V

ViroGates A/S
CSE:VIRO

Watchlist Manager
ViroGates A/S
CSE:VIRO
Watchlist
Price: 11.9 DKK -1.65% Market Closed
Market Cap: 92.1m DKK
Have any thoughts about
ViroGates A/S?
Write Note

ViroGates A/S
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ViroGates A/S
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
V
ViroGates A/S
CSE:VIRO
Gross Profit
kr2.4m
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GN Store Nord A/S
CSE:GN
Gross Profit
kr9.4B
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
8%
Ambu A/S
CSE:AMBU B
Gross Profit
kr3.2B
CAGR 3-Years
9%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Demant A/S
CSE:DEMANT
Gross Profit
kr16.9B
CAGR 3-Years
10%
CAGR 5-Years
8%
CAGR 10-Years
10%
No Stocks Found

ViroGates A/S
Glance View

Market Cap
92.1m DKK
Industry
Health Care

ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

VIRO Intrinsic Value
3.15 DKK
Overvaluation 73%
Intrinsic Value
Price
V

See Also

What is ViroGates A/S's Gross Profit?
Gross Profit
2.4m DKK

Based on the financial report for Sep 30, 2024, ViroGates A/S's Gross Profit amounts to 2.4m DKK.

What is ViroGates A/S's Gross Profit growth rate?
Gross Profit CAGR 3Y
-25%

Over the last year, the Gross Profit growth was -56%. The average annual Gross Profit growth rates for ViroGates A/S have been -25% over the past three years .

Back to Top